Search    ENTER KEYWORD
MSDS Material Safety Data Sheet
CAS

N/A

File Name: msds-gsk_com---13179002.asp
SDS Number 131790            Approved/Revised 03-Apr-2008                                                   Version 2
DYNACIRC CR CONTROLLED RELEASE TABLETS
Material



SAFETY DATA SHEET




1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND OF THE
COMPANY/UNDERTAKING
space




Material DYNACIRC CR CONTROLLED RELEASE TABLETS
space



DYNACIRC CR 5 MG CONTROLLED RELEASE TABLETS * DYNACIRC CR 10 MG
Synonym(s)
CONTROLLED RELEASE TABLETS * NDC NO. 65726-235-10 * NDC NO. 65726-236-10 *
ISRADIPINE, FORMULATED PRODUCT
space



GlaxoSmithKline, Corporate Environment, Health & Safety
Company Name
2200 Renaissance Blvd, Suite 105
King of Prussia, PA, 19406 US
space



Transport Emergency (non EU) +1-703-527-3887
US number, available 24 hours
Multi-language response
Medical Emergency +1-612-221-3999, Ext 221
space



GlaxoSmithKline, Corporate Environment, Health & Safety
One Franklin Plaza, 200 N 16th Street
Philadelphia, PA 19102-1225 US
space



US General Information: +1-888-825-5249
Transport Emergency (non EU) +1-703-527-3887
US number, available 24 hours
Multi-language response
.




2. COMPOSITION / INFORMATION ON INGREDIENTS
space




Ingredients CAS # Percent EC-No.
ISRADIPINE 75695-93-1 2.8 to 2.9
NON-HAZARDOUS INGREDIENTS Unassigned 97.1 to 97.2

3. HAZARDS IDENTIFICATION
space



Expected to be non-combustible.
Fire and Explosion
space



Handling this product in its final form presents minimal risk from occupational exposure.
Health
Health effects information is based on hazards of components.
space



No information is available about the potential of this product to produce adverse
Environment
environmental effects.

4. FIRST-AID MEASURES
space



Never attempt to induce vomiting. Do not attempt to give any solid or liquid by mouth if the
Ingestion
exposed subject is unconscious or semi-conscious. Wash out the mouth with water. If the
exposed subject is fully conscious, give plenty of water to drink. Obtain medical attention.
space



Physical form suggests that risk of inhalation exposure is negligible.
Inhalation
space



Using appropriate personal protective equipment, remove contaminated clothing and flush
Skin Contact
exposed area with large amounts of water. Obtain medical attention if skin reaction occurs,
which may be immediate or delayed.
space



Wash immediately with clean and gently flowing water. Continue for at least 15 minutes.
Eye Contact
Obtain medical attention.

Page 1 / 3
SDS Number 131790 Approved/Revised 03-Apr-2008 Version 2
DYNACIRC CR CONTROLLED RELEASE TABLETS
Material

space




NOTES TO HEALTH PROFESSIONALS
None.
Medical Treatment
space



None for occupational exposure.
Medical Conditions
Caused or Aggravated by
Exposure
space



No specific antidotes are recommended.
Antidotes
.




5. FIRE-FIGHTING MEASURES
space



Not expected for the product, although the packaging is combustible.
Fire and Explosion Hazards
space



Water or foam extinguishers are recommended.
Extinguishing Media
Carbon dioxide or dry powder extinguishers may be ineffective.
space



For single units (packages): No special requirements needed.
Special Firefighting
For larger amounts (multiple packages/pallets) of product: Since toxic, corrosive or
Procedures
flammable vapours might be evolved from fires involving this product and associated
packaging, self contained breathing apparatus and full protective equipment are
recommended for firefighters.
If possible, contain and collect firefighting water for later disposal.
space



Toxic, corrosive or flammable thermal decomposition products are expected when the
Hazardous Combustion
product is exposed to fire.
Products

6. ACCIDENTAL RELEASE MEASURES
space



Wear protective clothing and equipment consistent with the degree of hazard.
Personal Precautions
space



For large spills, take precautions to prevent entry into waterways, sewers, or surface drainage
Environmental Precautions
systems.
space



Collect and place it in a suitable, properly labelled container for recovery or disposal.
Clean-up Methods
space



No specific decontamination or detoxification procedures have been identified for this
Decontamination Procedures
product.

7. HANDLING AND STORAGE
space




HANDLING
Avoid breaking or crushing tablets.
General Requirements
space



No storage requirements necessary for occupational hazards. Follow product information
STORAGE
storage instructions to maintain efficacy.

8. EXPOSURE CONTROLS / PERSONAL PROTECTION
space
space



None required for normal handling. Wash hands and arms thoroughly after handling.
Other Equipment or
Procedures

9. PHYSICAL AND CHEMICAL PROPERTIES
space




Appearance
Tablet.
Physical Form

10. STABILITY AND REACTIVITY
space



This product is expected to be stable.
Stability
space



None for normal handling of this product.
Conditions to Avoid

11. TOXICOLOGY INFORMATION
space



This preparation contains ingredient(s) with the following activity: calcium channel blocker.
Pharmacological Effects
space



Adverse effects might occur in the following organ(s) following overexposure: cardiovascular
Target Organ Effects
system; heart.

Page 2 / 3
SDS Number 131790 Approved/Revised 03-Apr-2008 Version 2
DYNACIRC CR CONTROLLED RELEASE TABLETS
Material

space




Routes of Exposure
Not expected to be toxic following ingestion.
Oral Toxicity
space



No studies have been conducted.
Inhalation Toxicity
space



Minor irritation might occur following direct contact.
Skin Effects
space



Irritation is not expected following direct contact with eyes.
Eye Effects
space



Potential for inducing allergic reactions via the dermal or respiratory route is not known.
Sensitisation
space



Genetic toxicity is not expected under occupational exposure conditions based upon negative
Genetic Toxicity
results in laboratory assays.
space



Not expected to produce cancer in humans under occupational exposure conditions.
Carcinogenicity
space



Not expected to produce adverse effects on fertility or development under occupational
Reproductive Effects
exposure conditions.
space



The following adverse effects have been noted with therapeutic use of this material:
Other Adverse Effects
decreased blood pressure; increased heart rate; oedema; dizziness; fatigue; headache;
flushing; rash.

12. ECOLOGICAL INFORMATION
space



No information is available about the potential of this product to produce adverse
Summary
environmental effects. Local regulations and procedures should be consulted prior to
environmental release.

13. DISPOSAL CONSIDERATIONS
space



Collect for recycling or recovery if possible. The disposal method for rejected
Disposal Recommendations
products/returned goods must ensure that they cannot be re-sold or re-used.
space



Observe all local and national regulations when disposing of this product.
Regulatory Requirements

14. TRANSPORT INFORMATION
space



The SDS should accompany all shipments for reference in the event of spillage or accidental release. Only authorised persons
trained and competent in accordance with appropriate national and international regulatory requirements may prepare dangerous
goods for transport.
space




UN Classification and Labelling
Transportation and shipping of this product is not restricted. It has no known,
Transport Information
significant hazards requiring special packaging or labelling for air, maritime, US or
European ground transport purposes.

15. REGULATORY INFORMATION
space



The information included below is an overview of the major regulatory requirements. It should not be considered to be an
exhaustive summary. Local regulations should be consulted for additional requirements.
space




EU Classification and Labelling
Exempt from requirements of EU Dangerous Preparations directive - product regulated as a medicinal product,
cosmetic product or medical device.
space




US OSHA Standard (29 CFR Part 1910.1200)
Exempt when packaged for sale to consumers in a retail establishment.
Classification
space




Other US Regulations
Exempt
TSCA Status

16. OTHER INFORMATION
space



GSK Hazard Determination
References
space



2
SDS Version Number
space



The information and recommendations in this safety data sheet are, to the best of our knowledge, accurate as of the date of
issue. Nothing herein shall be deemed to create any warranty, express or implied. It is the responsibility of the user to determine
the applicability of this information and the suitability of the material or product for any particular purpose.

Page 3 / 3

Search    ENTER KEYWORD
ALL Chemical Property And Toxicity Analysis PAGES IN THIS GROUP
NAMECAS
msds-gsk_com---12906801.asp 44-20-8 95233-18-4 637-32-1
msds-gsk_com---12906803.asp 44-20-8 95233-18-4 637-32-1
msds-gsk_com---12912204.asp 44-20-8 471-34-1
msds-gsk_com---12912403.asp 44-20-8 96829-58-2
msds-gsk_com---12912701.asp 44-20-8 242478-38-2
msds-gsk_com---12912702.asp N/A
msds-gsk_com---129567.asp 170098-38-1
msds-gsk_com---12986903.asp 44-20-8
msds-gsk_com---13025801.asp 138926-19-9
msds-gsk_com---13034607.asp 44-20-8
msds-gsk_com---13038002.asp 44-20-8 7681-49-4 7757-79-1 13463-67-7
msds-gsk_com---13042602.asp 44-20-8
msds-gsk_com---13042603.asp 44-20-8
msds-gsk_com---13049401.asp 44-20-8
msds-gsk_com---13054402.asp 44-20-8
msds-gsk_com---13074101.asp 44-20-8 15687-27-1 41444-62-6
msds-gsk_com---13097201.asp 44-20-8 9005-80-5
msds-gsk_com---13097301.asp 44-20-8 9005-80-5 471-34-1 67-97-0
msds-gsk_com---13164201.asp 44-20-8
msds-gsk_com---13166901.asp 44-20-8
msds-gsk_com---13174601.asp 44-20-8
msds-gsk_com---13175101.asp 44-20-8
msds-gsk_com---13175201.asp 44-20-8
msds-gsk_com---13179002.asp N/A
oldbridgechem_com---msdsmaxetchclstarter.asp 1344-67-8 7647-01-0
panasonic_com---panasonic_liion_info.asp N/A
panasonic_com---panasonic_lithiumcr_info.asp 1313-13-9 7439-93-2 108-32-7 110-71-4 33454-82-9 7791-03-9
panasonic_com---prodnotice_ca_perchlorate_notice_cr_coin_06-2008.asp N/A
pickeringlabs_com---1700-0060.asp 7647-01-0 108-95-2
pickeringlabs_com---1700-0063.asp 1646-88-4 116-06-3 63-25-2 67-56-1
pickeringlabs_com---dmab_3700-0400.asp 100-10-7
pickeringlabs_com---glufosinate.asp 77182-82-2
pickeringlabs_com---k130.asp 1310-58-3
pickeringlabs_com---od104_&_ga104.asp 12045-78-2
pickeringlabs_com---opa.asp 643-79-8
pickeringlabs_com---seraprep.asp 5965-83-3
pickeringlabs_com---trione.asp 126-33-0
silicates_com---a-11-msds-fre.asp 7732-18-5 1344-09-8
silicates_com---a-13-msds-fre.asp 7732-18-5 1344-09-8
silicates_com---a13-msds.asp 7732-18-5 1344-09-8
silicates_com---b-26-msds-fre.asp 7732-18-5 1344-09-8
silicates_com---b26-msds.asp 7732-18-5 1344-09-8
silicates_com---britesilc20-msds-fre.asp 1344-09-8 7732-18-5
silicates_com---britesilc24-msds.asp 1344-09-8 7732-18-5
silicates_com---britesilh20-msds-fre.asp 1344-09-8 7732-18-5
silicates_com---britesilh24-msds-fre.asp 1344-09-8 7732-18-5
silicates_com---britesilh24-msds.asp 1344-09-8 7732-18-5
silicates_com---bw43-msds.asp 7732-18-5 1344-09-8
silicates_com---bw50-msds.asp 7732-18-5 1344-09-8
silicates_com---corebond-msds-fre_.asp 7732-18-5 1344-09-8

Free MSDS Search ( Providing 250,000+ Material Properties )
Chemcas.com | Ads link:HBCCHEM.INC